| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA i...
Telix Pharmaceuticals (NASDAQ:TLX) sees Q3 sales of $206.000 million.
Telix Pharmaceuticals (NASDAQ:TLX) raises FY2025 sales outlook from $770.000 million-$800.000 million to $800.000 million-$820....
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the United States (U.S.) Centers for...
Citigroup analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:TLX) with a Buy rating and announces P...
